To assess the anti-tumor efficacy of anti-Dll4 and anti-Dll4/VEGF combination therapy in a sunitinib resistant xenograft model, SCID mice were implanted subcutaneously with RP-R-01 tissue and treated with sunitinib until resistance was observed (when tumor size doubled that of pretreatment size). The gene discussed is DLL4; the disease is neoplasm.